Helus Pharma (NASDAQ: HELP) (Cboe CA: HELP), a clinical-stage pharmaceutical company developing novel serotonergic agonists, issued a correction to its April 28, 2026 release regarding its partnership with TARA Mind. The correction removes references to Veterans Exploring Treatment Solutions from earlier paragraphs while reaffirming the collaboration's alignment with a recent executive order aimed at advancing mental health treatments and clinical research participation.
The partnership with TARA Mind is intended to support Phase 3 recruitment for Helus Pharma's HLP003 program in major depressive disorder and expand outreach in veteran communities. The correction ensures clarity regarding the specific organizations involved in the collaboration.
Helus Pharma, the commercial operating name of Cybin Inc., is focused on developing proprietary NSAs (novel serotonergic agonists) designed to activate serotonin pathways believed to promote neuroplasticity. The company's lead candidate, HLP003, is in Phase 3 clinical development for the adjunctive treatment of major depressive disorder and has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration. Additionally, HLP004 is in Phase 2 for generalized anxiety disorder.
The company's efforts align with a recent executive order aimed at improving mental health treatments and increasing clinical research participation, particularly among veteran communities. The TARA Mind partnership is expected to facilitate recruitment for the HLP003 trial and expand access to innovative therapies for those who have served.
For more information, view the full press release here. Updates on Helus Pharma are available at www.helus.com or by following the team on social media. InvestorWire, a specialized communications platform, syndicated this press release as part of its services. For more details, visit InvestorWire.
